Roberts, Glore & Co’s Novartis NVS Stock Holding History

Roberts, Glore & Co’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92M	Sell	12,568 -205	-2%	-$31.4K	0.53%	48
2025 Q4	$1.76M	Sell	12,773 -370	-3%	-$48.5K	0.47%	50
2025 Q3	$1.69M	Sell	13,143 -365	-3%	-$44.5K	0.46%	54
2025 Q2	$1.63M	Sell	13,508 -631	-4%	-$71.1K	0.48%	55
2025 Q1	$1.58M	Hold	14,139	–	–	0.48%	55
2024 Q4	$1.38M	Sell	14,139 -195	-1%	-$20.8K	0.41%	64
2024 Q3	$1.65M	Sell	14,334 -357	-2%	-$40.5K	0.48%	59
2024 Q2	$1.56M	Sell	14,691 -252	-2%	-$25.3K	0.47%	58
2024 Q1	$1.45M	Sell	14,943 -588	-4%	-$60.3K	0.43%	65
2023 Q4	$1.57M	Sell	15,531 -1,145	-7%	-$111K	0.49%	56
2023 Q3	$1.7M	Sell	16,676 -250	-1%	-$25.4K	0.56%	47
2023 Q2	$1.71M	Sell	16,926 -36	-0.2%	-$3.6K	0.55%	48
2023 Q1	$1.56M	Sell	16,962 -100	-0.6%	-$8.73K	0.52%	54
2022 Q4	$1.55M	Buy	17,062 +380	+2%	+$32K	0.54%	51
2022 Q3	$1.27M	Hold	16,682	–	–	0.45%	59
2022 Q2	$1.41M	Buy	16,682 +112	+0.7%	+$9.83K	0.47%	58
2022 Q1	$1.45M	Buy	16,570 +100	+0.6%	+$8.66K	0.42%	60
2021 Q4	$1.44M	Sell	16,470 -433	-3%	-$36K	0.38%	59
2021 Q3	$1.38M	Buy	16,903 +50	+0.3%	+$4.5K	0.42%	62
2021 Q2	$1.54M	Sell	16,853 -100	-0.6%	-$8.9K	0.46%	60
2021 Q1	$1.45M	Sell	16,953 -262	-2%	-$23.5K	0.45%	61
2020 Q4	$1.63M	Sell	17,215 -22	-0.1%	-$1.92K	0.53%	53
2020 Q3	$1.5M	Sell	17,237 -20	-0.1%	-$1.73K	0.53%	54
2020 Q2	$1.51M	Sell	17,257 -500	-3%	-$43.2K	0.59%	47
2020 Q1	$1.46M	Hold	17,757	–	–	0.63%	52
2019 Q4	$1.68M	Buy	17,757 +6,341	+56%	+$569K	0.64%	49
2019 Q3	$992K	Hold	11,416	–	–	0.61%	50
2019 Q2	$1.04M	Sell	11,416 -1,399	-11%	-$118K	0.64%	49
2019 Q1	$1.1M	Sell	12,815 -502	-4%	-$40.3K	0.69%	47
2018 Q4	$1.02M	Sell	13,317 -591	-4%	-$46K	0.72%	45
2018 Q3	$1.07M	Buy	13,908 +204	+1%	+$15.1K	0.62%	49
2018 Q2	$928K	Sell	13,704 -224	-2%	-$15.5K	0.57%	54
2018 Q1	$1.01M	Sell	13,928 -83	-0.6%	-$6.32K	0.62%	51
2017 Q4	$1.05M	Sell	14,011 -447	-3%	-$33.7K	0.64%	47
2017 Q3	$1.11M	Buy	14,458 +279	+2%	+$21.1K	0.72%	40
2017 Q2	$1.06M	Buy	14,179 +184	+1%	+$13K	0.71%	44
2017 Q1	$931K	Sell	13,995 -892	-6%	-$59.4K	0.64%	48
2016 Q4	$972K	Buy	14,887 +390	+3%	+$25.3K	0.68%	46
2016 Q3	$1.03M	Sell	14,497 -84	-0.6%	-$6.12K	0.74%	43
2016 Q2	$1.08M	Buy	14,581 +224	+2%	+$15.5K	0.82%	38
2016 Q1	$932K	Buy	14,357 +669	+5%	+$45.5K	0.71%	46
2015 Q4	$1.05M	Sell	13,688 -83	-0.6%	-$6.59K	0.8%	42
2015 Q3	$1.13M	Sell	13,771 -558	-4%	-$49.7K	0.89%	36
2015 Q2	$1.26M	Sell	14,329 -201	-1%	-$18.4K	0.88%	35
2015 Q1	$1.28M	Sell	14,530 -4,358	-23%	-$387K	0.89%	37
2014 Q4	$1.57M	Sell	18,888 -45	-0.2%	-$3.73K	1.05%	32
2014 Q3	$1.6M	Sell	18,933 -39	-0.2%	-$3.15K	1.11%	26
2014 Q2	$1.54M	Sell	18,972 -558	-3%	-$43.9K	1.04%	31
2014 Q1	$1.49M	Sell	19,530 -1,841	-9%	-$134K	1.03%	32
2013 Q4	$1.54M	Buy	21,371 +306	+1%	+$21.3K	1.07%	32
2013 Q3	$1.45M	Sell	21,065 -8,303	-28%	-$549K	1.07%	31
2013 Q2	$1.86M	Buy	+29,368	New	+$1.91M	1.15%	26

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Roberts, Glore & Co's NVS Position: Q1 2026 in Review

Roberts, Glore & Co reduced its Novartis (NVS) stake by 1.6% in Q1 2026, selling an estimated $31.4K and leaving 12,568 shares worth $1.92M. The position accounts for 0.53% of the portfolio, ranked #48.

Roberts, Glore & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Roberts, Glore & Co held 12,568 shares of Novartis worth $1.92M as of Q1 2026.
Roberts, Glore & Co sold 205 Novartis shares in Q1 2026, an estimated $31.4K.
Novartis made up 0.53% of Roberts, Glore & Co's portfolio in Q1 2026, its #48 holding.
Roberts, Glore & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.